AYTU BIOPHARMA, INC current report, 22 October 2018

Full document

Business Context and Reporting Period

This Form 8-K was filed by Aytu Bioscience, Inc. on October 22, 2018. The report discloses a change in the Company's independent registered public accounting firm. Effective October 1, 2018, EKS&H LLLP combined with Plante & Moran PLLC. Consequently, on October 19, 2018, the Company engaged Plante Moran as its new auditor, and EKS&H resigned.

Key Financial Metrics

This filing does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses solely on the administrative change of the auditing firm.

Material Changes and Audit History

  • Accounting Disagreements: The Company reported no disagreements with EKS&H regarding accounting principles, financial statement disclosure, or auditing scope during the fiscal years ended June 30, 2018 and 2017, or the interim period preceding the new appointment.
  • Reportable Events: No reportable events occurred during the same periods.
  • Audit Opinions: The audit reports for the years ended June 30, 2018 and 2017 did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty or scope. However, the 2018 audit report included an explanatory paragraph indicating substantial doubt about the Company's ability to continue as a going concern.
  • Consultations: The Company did not consult with Plante Moran on accounting principles or audit opinions prior to their engagement.

Guidance, Outlook, and Risks

The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the historical note regarding the "substantial doubt" about the Company's ability to continue as a going concern noted in the 2018 audit report.

Investor Verification Checklist

  • Verify the status of the "substantial doubt" regarding the Company's ability to continue as a going concern as of the most recent financial statements.
  • Confirm the transition timeline and responsibilities between EKS&H and Plante Moran.
  • Review the letter from EKS&H (Exhibit 16.1) to ensure they agree with the Company's statements regarding the resignation and lack of disagreements.